Darolutamide

Darolutamide is an oral non-steroidal androgen receptor inhibitor used in the treatment of prostate cancer. It works by binding to androgen receptors and blocking androgen-dependent signaling, including receptor activation, movement of the receptor into the cell nucleus, and androgen receptor-mediated transcription. This reduces signaling pathways that can support prostate cancer cell growth. Darolutamide has relatively low penetration across the blood-brain barrier compared with some other androgen receptor inhibitors, which is an important pharmacological characteristic. It is administered orally as film-coated tablets and is generally taken twice daily with food. Darolutamide is used alongside androgen-deprivation therapy in patients who have not undergone surgical castration. Depending on the disease setting and regulatory approval, it may be used alone with androgen-deprivation therapy or as part of a combination regimen that includes docetaxel. Its clinical importance is supported by phase 3 studies showing improvements in outcomes for patients with non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer.

Darolutamide was developed as a structurally distinct androgen receptor antagonist for prostate cancer, with its pharmacological activity based on inhibition of androgen receptor signaling. The phase 3 ARAMIS study established its clinical efficacy in men with high-risk non-metastatic castration-resistant prostate cancer, while the ARASENS study evaluated darolutamide with androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer. Darolutamide received its initial approval from the U.S. Food and Drug Administration in 2019 for non-metastatic castration-resistant prostate cancer. The European Commission issued marketing authorization in the European Union in March 2020. In June 2025, the FDA expanded the indication to metastatic castration-sensitive prostate cancer, including use with androgen-deprivation therapy and use in combination with docetaxel. European regulatory information includes use in non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer with androgen-deprivation therapy, with or without docetaxel.

Darolutamide is indicated for adult patients with non-metastatic castration-resistant prostate cancer and for metastatic castration-sensitive prostate cancer, subject to the specific indication and regulatory labeling applicable in the treatment setting. In patients with metastatic castration-sensitive prostate cancer, darolutamide may be used with androgen-deprivation therapy, and it may also be combined with androgen-deprivation therapy and docetaxel when the approved regimen is appropriate. Patients receiving medical androgen-deprivation therapy generally continue a GnRH agonist or antagonist unless they have undergone bilateral orchiectomy. In non-metastatic castration-resistant disease, darolutamide is used with continued androgen-deprivation therapy. The ARAMIS clinical program supported its use in high-risk non-metastatic castration-resistant disease, while ARASENS demonstrated the clinical benefit of adding darolutamide to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive disease.

Darolutamide is administered orally as 300 mg tablets, with the standard adult dose being 600 mg twice daily, taken with food and swallowed whole. Treatment is generally continued until disease progression or unacceptable toxicity. Patients receiving darolutamide should also receive appropriate androgen-deprivation therapy unless they have undergone bilateral orchiectomy. When darolutamide is used with docetaxel for metastatic castration-sensitive prostate cancer, the first docetaxel cycle is administered within 6 weeks of starting darolutamide, with the combination generally involving six planned cycles of docetaxel. If a patient develops a severe or intolerable adverse reaction, treatment may be temporarily withheld or the dose reduced under medical supervision. A reduced dose of 300 mg twice daily is recommended for patients with severe renal impairment who are not receiving hemodialysis and for patients with moderate hepatic impairment.

Common side effects vary according to the disease setting and whether darolutamide is administered with androgen-deprivation therapy alone or together with docetaxel. Frequently reported adverse effects and laboratory abnormalities include fatigue, increased liver enzymes such as AST and ALT, increased bilirubin, reduced neutrophil counts, rash, pain in the extremities, and urinary tract infection. When darolutamide is combined with docetaxel, constipation, rash, decreased appetite, bleeding, weight increase, hypertension, anemia, changes in blood glucose, reduced lymphocyte or neutrophil counts, increased liver enzymes, and low calcium levels may occur. Some adverse effects may be related to androgen-deprivation therapy or docetaxel rather than darolutamide alone, so clinical assessment is important when symptoms develop.

Important warnings associated with darolutamide include ischemic heart disease, seizures, and embryo-fetal toxicity. Patients with cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, or established cardiovascular disease require appropriate assessment and monitoring, and signs or symptoms suggestive of ischemic heart disease should be evaluated promptly. Seizures have been reported and treatment discontinuation may need to be considered if a seizure occurs. Darolutamide can cause fetal harm based on its mechanism of action, and males with partners of reproductive potential should use effective contraception during treatment and for one week after the final dose. There are no formal contraindications listed in the current U.S. prescribing information, but clinically significant adverse reactions may require treatment interruption, dose reduction, or discontinuation.

Before treatment, clinicians should review cardiovascular history, renal and hepatic function, concurrent medicines, and the patient's overall prostate cancer treatment plan. Darolutamide should be used with appropriate androgen-deprivation therapy when indicated. Important drug interactions involve metabolic enzymes and transporters. Combined P-glycoprotein and strong or moderate CYP3A4 inducers should generally be avoided because they can reduce darolutamide exposure, while combined P-glycoprotein and strong CYP3A4 inhibitors can increase exposure and may require closer monitoring or dose modification. Darolutamide can inhibit BCRP and OATP1B1 and OATP1B3 transporters and may therefore increase concentrations of certain medicines that are substrates of these transporters. Renal and hepatic impairment may require dose adjustment. Pregnancy should be avoided because of the potential for embryo-fetal harm.

Prescribers and pharmacists should confirm the disease setting, testosterone-control strategy, concurrent systemic therapies, renal and hepatic function, and the complete medication list before treatment. Darolutamide should be taken consistently with food and tablets should be swallowed whole. PSA and clinical disease status should be followed according to the patient's prostate cancer management plan, while laboratory monitoring should include appropriate assessment of liver function and blood counts, particularly when darolutamide is combined with docetaxel. Cardiovascular risk factors should be actively managed, and patients should be counselled to report symptoms such as chest discomfort, shortness of breath, palpitations, or neurological events. When docetaxel is part of the regimen, toxicity monitoring should account for the adverse-effect profile of both medicines and treatment coordination should follow the relevant prescribing information.